🇺🇸 FDA
Pipeline program

Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

UC-SAR-2212_L-UteCIN

Phase 2 small_molecule active

Quick answer

Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion for Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials